Tarsus Pharmaceuticals (TARS) Interest & Investment Income (2019 - 2026)

Tarsus Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 7.76% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $16.0 million (up 4.33% YoY), while the FY2025 annual figure was $15.7 million, up 4.88% from the prior year.
• Interest & Investment Income was $3.7 million for Q1 2026 at Tarsus Pharmaceuticals, down from $4.0 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.2 million in Q2 2025 to a low of $297000.0 in Q2 2022.
• Historically, Interest & Investment Income has averaged $3.0 million across 5 years, with a median of $3.3 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 17625.0% in 2022, then dropped 0.15% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $2.1 million in 2022, then jumped by 40.01% to $3.0 million in 2023, then grew by 22.46% to $3.6 million in 2024, then climbed by 8.31% to $4.0 million in 2025, then decreased by 5.77% to $3.7 million in 2026.
• The last three Interest & Investment Income figures came in at $3.7 million (Q1 2026), $4.0 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.